CoproBan® Soft Chews are now available in a 40-count jar featuring updated consumer-friendly packaging and improved pet acceptance, helping make canine coprophagia (the eating of feces) easier to control.
![New CoproBan® Packaging Makes Coprophagia Control Convenient](https://www.prnpharmacal.com/wp-content/uploads/2020/11/CoproBan_SoftChew_40ct_Front-1000x675.png)
Home » News & Updates
CoproBan® Soft Chews are now available in a 40-count jar featuring updated consumer-friendly packaging and improved pet acceptance, helping make canine coprophagia (the eating of feces) easier to control.
The U.S. Food and Drug Administration (FDA) has approved Firocoxib Tablets for Dogs. To be marketed under the brand name Sē•Qual™, Firocoxib Chewable Tablets for Dogs joins Firocoxib Tablets for Horses as the second generic nonsteroidal anti-inflammatory drug (NSAID)...
Pegasus Laboratories dba PRN Pharmacal will transition from chicken-based protein flavoring in its prescription product, KBroVet®-CA1 (potassium bromide chewable tablets) to a new French vanilla flavor. The FDA-approved change comes in response to concerns regarding...
PRN® Pharmacal has enhanced the UniversityPRN.com training module site. Focusing on a better partnership between customer service and distribution sales representatives, the site currently features six product-specific training modules, each ranging from three to five...
The U.S. Food and Drug Administration (FDA) has approved Firocoxib Tablets for Horses. To be marketed under the brand name Sē•Qual™, Firocoxib Tablets for Horses will be the first generic nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation...
PRN® Pharmacal has updated the product labels on their line of veterinary nutritional supplements. The new labels are designed to make information more clear and concise for both the veterinarian and the pet owner. Products with updated labels include: STAT® High...
Pegasus Laboratories dba PRN Pharmacal made a major investment in its future by acquiring the property neighboring their Pensacola facility. This new property, which includes a 169,000 square foot building situated on 10 acres, will nearly triple its manufacturing...
In an effort to offer industry professionals more continuing education course options, PRN® Pharmacal partnered with Clinician’s Brief to leverage their existing comprehensive training platform. Effective January 1, 2022, all UniversityPRN.com courses were transferred...
The US Food and Drug Administration has granted KBroVet®-CA1 (potassium bromide chewable tablets) conditional approval for veterinary use in the management of seizures in dogs with idiopathic epilepsy. PRN® Pharmacal developed KBroVet-CA1 to provide a consistent and...